Perfuze develops next-generation catheter-based aspiration technology to treat acute ischemic stroke, with a proprietary platform designed to maximize clot removal efficiency and simplify procedures. The company’s Zipline™ Access Catheters, cleared by the FDA via 510(k), are engineered to improve trackability and deliver large (070) and superbore (088) aspiration catheters. Perfuze has initiated a Limited Market Release in U.S. Comprehensive Stroke Centres and is rolling out the Zipline™ alongside its Millipede™ catheters. The company is headquartered in Galway, Ireland, and emphasizes faster, easier navigation to accelerate reperfusion and improve clinical outcomes. Recent funding will support the U.S. Limited Market Release, ongoing clinical programs, and R&D to further enhance its stroke-treatment portfolio. Perfuze develops super-bore diameter aspiration catheter technology (the Millipede System) intended to navigate complex neurovascular anatomy and enable fast, complete clot removal in acute ischemic stroke. The company holds CE Mark approval for its first device, Millipede 088, and has treated its first cohort of patients. Proceeds from the Series A will fund the next stage of U.S. clinical study and regulatory clearance of the Millipede System, support ongoing product development, and initiate commercialization. Perfuze’s pipeline is focused on devices designed to shorten procedural times and improve clinical outcomes in large vessel occlusion stroke. The company was founded in 2018 by Wayne Allen and Liam Mullins and is based in Galway, Ireland. Perfuze is developing the Millipede platform, a next-generation catheter-based technology intended to treat acute ischemic stroke. The technology aims to deliver superior clinical outcomes in shorter procedural times, providing safe, cost-effective therapy. The company closed a €3 million seed investment to facilitate further development of the Millipede platform. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins, who together have over 30 years of medtech experience. The company is based at the Business Innovation Centre on the campus of the National University of Ireland, Galway and is relocating to the IDA Business Park in Dangan, Galway.

Total raised

$55M

Funding rounds

3

Latest round

Equity

Latest activity

Mar 2025